Abstract
Small cell lung cancer (SCLC) is a highlyaggressive and refractory lung cancer. Most patients respond to first-linechemotherapy but relapse rapidly, resulting in a relatively poor prognosis. Inthe past few years, immunotherapy, especially the immune checkpoint inhibitorsrepresented by PD-L1 inhibitors, has made initial progress in SCLC. Butdifferent patients respond differently to treatment, and it is necessary todetermine which part of patients benefit the most.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.